XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets, Net
 9 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
Goodwill
The Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2024 and fiscal 2023 did not indicate any impairment of goodwill.
Changes in the carrying amount of goodwill were as follows:
(In millions)
U.S. Pharmaceutical (1)
Prescription Technology SolutionsMedical-Surgical Solutions
International
Total
Balance, March 31, 2023$4,050 $2,005 $2,453 $1,439 $9,947 
Goodwill acquired— — — 3 3 
Foreign currency translation adjustments, net— — — 30 30 
Other adjustments (2)
(7)— — — (7)
Balance, December 31, 2023$4,043 $2,005 $2,453 $1,472 $9,973 
(1)The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe’s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.
(2)Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, “Business Acquisitions and Divestitures.”
Intangible Assets
Information regarding intangible assets was as follows:
 December 31, 2023March 31, 2023
(Dollars in millions)Weighted-
Average
Remaining
Amortization
Period
(Years)		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships11$1,800 $(676)$1,124 $2,971 $(1,765)$1,206 
Service agreements101,131 (663)468 1,137 (623)514 
Trademarks and trade names12760 (388)372 833 (430)403 
Technology10244 (120)124 264 (129)135 
Other633 (24)9 193 (174)19 
Total (1)
 $3,968 $(1,871)$2,097 $5,398 $(3,121)$2,277 
(1)During the third quarter of fiscal 2024, the Company performed a review of its intangible assets and removed from the balance sheet $1.4 billion of fully amortized gross intangible assets and the corresponding accumulated amortization associated with the assets that no longer provide an economic benefit, are no longer in use, or for which the related contract has expired.
All intangible assets were subject to amortization as of December 31, 2023 and March 31, 2023. Amortization expense of intangible assets was $62 million and $57 million for the three months ended December 31, 2023 and 2022, respectively, and $186 million and $170 million for the nine months ended December 31, 2023 and 2022, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $62 million, $240 million, $208 million, $202 million, and $198 million for the remainder of fiscal 2024 and each of the succeeding years through fiscal 2028, respectively, and $1.2 billion thereafter.